Significance of serum protein S100 levels in screening for melanoma metastasis: Does protein S100 enable early detection of melanoma recurrence?

Melanoma Research

Volumn 10, Issue 5, 2000, Pages 451-459

  Schlagenhauff, B ^a   Schittek, B ^a   Ellwanger, U ^a   Stroebel, W ^a   Blum, A ^a   Schwarz, M ^a   Rassner, G ^a   Garbe, C ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Melanoma; Metastases; S100; Serum; Tumour marker

Indexed keywords

PROTEIN S 100; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC TEST; EARLY DIAGNOSIS; FOLLOW UP; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROTEIN ANALYSIS;

ADULT; CALCIUM-BINDING PROTEINS; DISEASE PROGRESSION; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; IMMUNORADIOMETRIC ASSAY; MALE; MELANOMA; NEOPLASM METASTASIS; NEOPLASM STAGING; NERVE GROWTH FACTORS; PREDICTIVE VALUE OF TESTS; RECURRENCE; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; S100 PROTEINS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0033773719     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200010000-00007     Document Type: Article

References (38)

1. Prognostic clinical and pathologic features
2. Primary cutaneous melanoma. Prognostic classification of anatomic location
3. Role of surgery for metastatic malignant melanoma: A review
4. Prolonged survival of 2 years or longer for patients with disseminated melanoma
5. Regression analyses of prognostic factors in metastatic malignant melanoma
6. Prognostic factors in patients with metastatic malignant melanoma
7. Laboratory tests and imaging studies in patients with cutaneous malignant melanoma
8. Neuron-specific enolase as a prognostic factor in metastatic malignant melanoma
9. S-100 and NSE as serum markers in melanoma
10. Clinical significance of serum S100 in metastatic malignant melanoma
11. Evaluation of new putative tumor markers for melanoma
12. Serum levels of sICAM-1 and 5-Scysteinyldopa as markers of melanoma progression
13. Evaluation of melanin-related metabolites as markers of melanoma progression
14. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma
15. Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma
16. Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: Association with clinical stage and prognosis
17. Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression
18. Amplification of MelanA messenger RNA in addition to tyrosinase increases sensitivity of melanoma cell detection in peripheral blood and is associated with the clinical stage and prognosis of malignant melanoma
19. A soluble protein characteristic of the nervous system
20. S100 protein: A marker for human malignant melanomas?
21. S-100 protein in soft tissue tumors derived from Schwann cells and melanocytes
22. Detection of S-100 protein as an aid to the identification of melanocytic tumors
23. S-100 protein and neuron specific enolase in cerebrospinal fluid and serum: Markers of cell damage in human central nervous system
24. Particle counting immunoassay of S100 protein in serum. Possible relevance in tumors and ischemic disorders of the central nervous system
25. Prognostic value of serum analyses of S-100 beta protein in malignant melanoma
26. Elevated serum levels of S100 and survival in metastatic malignant melanoma
27. The luminescence immunoassay S-100: A sensitive test to measure circulating S-100b: Its prognostic value in malignant melanoma
28. Serum S-100 protein: A potentially useful prognostic marker in cutaneous melanoma
29. Serum S100 - A marker for disease monitoring in metastatic melanoma
30. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma
31. Prognostic value of serum analyses of S-100 protein beta in malignant melanoma
32. S100 serum protein levels in cutaneous malignant melanoma
33. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma
34. Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients
35. Serum S-100 has prognostic significance in malignant melanoma
36. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system
37. Position paper of the melanoma committee of the German dermatological society on cutaneous malignant melanoma, with recommendations for diagnosis, treatment and follow up
38. A new American Joint Committee on Cancer staging system for cutaneous melanoma